Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Treasury Shares: 2014-2025

Historic Treasury Shares for Arrowhead Pharmaceuticals (ARWR) over the last 11 years, with Sep 2025 value amounting to $2.7 million.

  • Arrowhead Pharmaceuticals' Treasury Shares was N/A to $53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.2 million, marking a year-over-year change of. This contributed to the annual value of $53.2 million for FY2025, which is N/A change from last year.
  • As of FY2025, Arrowhead Pharmaceuticals' Treasury Shares stood at $53.2 million.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Treasury Shares peaked at $53.2 million during FY2025, and registered a low of $53.2 million during FY2025.
  • Moreover, its 2-year median value for Treasury Shares was $3.5 million (2023), whereas its average is $3.5 million.
  • Data for Arrowhead Pharmaceuticals' Treasury Shares shows a peak YoY climbed of 8.74% (in 2021) over the last 5 years.
  • Yearly analysis of 4 years shows Arrowhead Pharmaceuticals' Treasury Shares stood at $3.8 million in 2021, then rose by 6.21% to $4.1 million in 2022, then grew by 4.22% to $4.2 million in 2023, then reached $2.7 million in 2025.